1. The need for new agents - Tim Eden
2. Identifying pre-clinical agents - Shekhar Krishnan, Ashish Masurekar, and Vaskar Saha
3. Pre-clinical evaluation - Barbara Szymanska, Hernan Carol, and Richard Lock
4. Design of early phase trials - James Whitlock and Terzah Horton
5. Strategies for trial design and analyses - Grazia Maria Valsecchi
6. Overview on Molecular and Animal models of ALL - Michael Batey and Josef Vormoor
7. Apoptosis, BCL2 - Guy Makin and Caroline Dive
8. Targeting Stem Cells - Clare Pridans and Brian Huntly
9. Nucleoside Analogues - Pamela Kearns and Vaskar Saha
10. Flt3 Inhibitors - Ronald Stam and Rob Pieters
11. Tyrosine Kinase Inhibitors - Shaun Wilson
12. Monoclonal Antibodies - Arend von Stackelberg
13. Proteasome inhibitors - Joya Chandra and Claudia Miller
14. Targeting epigenetic pathways in ALL - Pamela Kearns
15. Incorporating new therapies in frontline protocols - Paul Gaynon and Theresa Harned